Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib - Eberhard, D A; Johnson, B E; Amler, L C (J Clin Oncol, 2005)
, et al.